Breast Cancer Proteomics and Molecular Heterogeneity
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorCancer Trials Ireland
About this trial
Primary objective:
The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes
Secondary objective:
* To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes. * To relate proteomic findings to survival data * To identify potential serum markers of breast cancer progression
Eligibility criteria
Qualifiers
Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue
Patients receiving neoadjuvant treatment are also eligible (if applicable)
Patients have to be ≥ 18 years of age
Patients must be able to give informed consent
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
1,780 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov